Tango Therapeutics, Inc. (TNGX)

NASDAQ: TNGX · IEX Real-Time Price · USD
11.80
+0.43 (3.78%)
Feb 27, 2024, 4:00 PM EST - Market closed
3.78%
Market Cap 1.16B
Revenue (ttm) 37.51M
Net Income (ttm) -100.04M
Shares Out 101.99M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 538,496
Open 11.47
Previous Close 11.37
Day's Range 11.34 - 11.95
52-Week Range 2.47 - 13.03
Beta 0.95
Analysts Strong Buy
Price Target 17.00 (+44.07%)
Earnings Date Mar 25, 2024

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 sil... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 110
Stock Exchange NASDAQ
Ticker Symbol TNGX
Full Company Profile

Financial Performance

In 2022, TNGX's revenue was $24.86 million, a decrease of -32.89% compared to the previous year's $37.04 million. Losses were -$108.18 million, 85.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 44.07% from the latest price.

Price Target
$17.0
(44.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...

27 days ago - GlobeNewsWire

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precisio...

7 weeks ago - GlobeNewsWire

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

STOCKHOLM , Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...

7 weeks ago - PRNewsWire

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers –

3 months ago - GlobeNewsWire

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 –

3 months ago - GlobeNewsWire

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...

4 months ago - GlobeNewsWire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision canc...

6 months ago - GlobeNewsWire

Tango Therapeutics Announces Updates to Its Board of Directors

BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...

6 months ago - GlobeNewsWire

Tango Therapeutics Announces $80 million Private Placement Financing

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...

7 months ago - GlobeNewsWire

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors –

7 months ago - GlobeNewsWire

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...

7 months ago - GlobeNewsWire

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, to...

8 months ago - GlobeNewsWire

Tango Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...

9 months ago - GlobeNewsWire

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers –

10 months ago - GlobeNewsWire

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meet...

11 months ago - GlobeNewsWire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision canc...

11 months ago - GlobeNewsWire

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

– Fast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor –

1 year ago - GlobeNewsWire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Resear...

1 year ago - GlobeNewsWire

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

BOSTON, March 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision canc...

1 year ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) Investigation

NEW YORK--(BUSINESS WIRE)---- $TNGX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BCTG Acquisition Corp., which me...

1 year ago - Business Wire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma

1 year ago - GlobeNewsWire

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France –

1 year ago - GlobeNewsWire

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, to...

1 year ago - GlobeNewsWire

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

TNG260 is in preclinical development as a first-in-class CoREST deacetylase inhibitor for the treatment of STK11-mutant cancers TNG260 is in preclinical development as a first-in-class CoREST deacetyl...

1 year ago - GlobeNewsWire

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer me...

1 year ago - GlobeNewsWire